Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.
Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
Current Team (4)Update
Past Team (6)Update
Interim Chief Financial Officer
2009 - Jan, 2012
Vice President, Molecular Discovery And Preclinical Development.
Executive Vice President, Chief Business Officer and Treasure
Mar, 2010 - Jul, 2013
2007 - Jan, 2010
Funding Rounds (5) - $61.5MUpdate
Board Members and Advisors (8)Update
Celgene discovers, develops and commercializes innovative therapies to treat cancer and...
HIV, TB pharmaceuticals
Leukemia & Lymphoma Society was founded in 1944
Global venture capital firm helping entrepreneurs build transformational businesses across...
Amgen engages in the development of human therapeutic products in supportive of cancer care,...
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing...
Healthcare Venture Capital
Corporate venture capital